MLTX |
MoonLake Immunotherapeutics |
Director, 10%+ Owner |
$64.4M |
-$100M |
-60.8% |
Oct 4, 2024 |
KYMR |
Kymera Therapeutics, Inc. |
Director, Other* |
$20.1M |
+$39.3M |
|
Aug 20, 2024 |
VSTM |
Verastem, Inc. |
10%+ Owner |
$10.9M |
|
|
Jan 25, 2022 |
MRUS |
Merus N.V. |
10%+ Owner |
$6.47M |
|
|
Oct 7, 2021 |
OLMA |
Olema Pharmaceuticals, Inc. |
Director, Other* |
$6.15M |
|
|
Dec 4, 2024 |
ELDN |
Eledon Pharmaceuticals, Inc. |
10%+ Owner |
$4.05M |
+$17.3M |
|
Oct 29, 2024 |
EPIX |
ESSA Pharma Inc. |
10%+ Owner |
$3.58M |
|
|
Jul 11, 2022 |
RPTX |
Repare Therapeutics Inc. |
10%+ Owner |
$2.96M |
|
|
Nov 15, 2023 |
THRD |
Third Harmonic Bio, Inc. |
Other* |
$2.53M |
-$14.3M |
-85% |
Oct 29, 2024 |
ALLK |
Allakos Inc. |
10%+ Owner |
$2.14M |
|
|
Jan 16, 2024 |
XOMA, XOMAO |
XOMA Royalty Corp |
Director, Other*, 10%+ Owner |
$1.91M |
|
|
May 17, 2023 |
FDMT |
4D Molecular Therapeutics, Inc. |
Other* |
$1.44M |
|
|
Nov 8, 2024 |
CGEM |
Cullinan Therapeutics, Inc. |
10%+ Owner |
$799K |
|
|
Jan 19, 2023 |
PIRS |
PIERIS PHARMACEUTICALS, INC. |
Other* |
$619K |
|
|
Dec 13, 2024 |
RAIN |
Rain Oncology Inc. |
Director, Other* |
$0 |
|
|
Jan 25, 2024 |
CTIC |
CTI BIOPHARMA CORP |
Director, Other*, 10%+ Owner |
|
|
|
Jun 26, 2023 |
ENGN, ENGNW |
enGene Holdings Inc. |
10%+ Owner |
|
|
|
Oct 31, 2023 |
PNT |
POINT Biopharma Global Inc. |
Former 10% Owner |
|
|
|
Dec 18, 2023 |
GPCR |
Structure Therapeutics Inc. |
10%+ Owner |
|
|
|
May 10, 2023 |